Arrive AI recorded Q4 2025 revenue of approximately $15,000 and full-year revenue of $113,000, driven entirely by recurring subscription fees. The company reported net losses of $2.7 million in Q4 and $12.8 million for the full year, exited with $2.1 million in cash and secured a $10 million draw from its credit facility in January 2026 to bolster liquidity.

On March 31, 2026, Arrive AI was granted its 10th patent, enhancing its competitive edge with protections for multi-user Arrive Point access, built-in sorting and storage, and coordination across autonomous systems. The company has accelerated its transition from the AP3 to AP5 platform, internalized key engineering functions, and implemented AI-driven simulations to support scalable deployments.

Arrive AI’s Arrive Points have been deployed in a live pilot with Hancock Health in Indiana for autonomous biospecimen transport between facilities. This deployment has reduced staff walking time, improved operational efficiency, and validated the technology’s ability to integrate into complex healthcare workflows with reliable performance.

The company expanded its ecosystem through collaborations with Ottonomy to ensure seamless robot interactions, participation in the NVIDIA Connect Program for AI model development, and the addition of a telecommunications expert to its board. These efforts support Arrive AI’s strategy to scale its network, refine use cases, and prepare for broader enterprise and healthcare rollouts.